News Archive

Surveys at 12 cancer centers across the U.S. looked at cannabis usage among cancer patients.

As people with HIV live longer, they are more likely to get cancers that come with age but HIV might complicate treatment.

Scientists at MUSC Hollings Cancer Center think it's possible that CAR-T-cell therapy could be performed without lymphodepleting chemotherapy beforehand.

A new method to study changes in sugars coating immune cells could potentially identify novel biomarkers and detect cancer earlier.

Three Hollings members – an M.D., a D.D.S. and a Ph.D. – are pooling their expertise to develop a personalized vaccine to prevent oral cancer from returning.

MUSC Hollings Cancer Center awarded a number of pilot grants through the spring and summer to kickstart research projects on a range of topics.

The Clinical Trialist Training Program offers early-career clinicians the time and know-how to lead clinical trials.

The role of e-cigarettes is hotly debated. A new study shows they could have a role in helping adult smokers to quit.

Hollings works with more than a dozen sites in South Carolina to bring clinical trials to the community, including the Ralph H. Johnson VA Health Care System.

MUSC Hollings Cancer Center is leading a national trial to test an intervention to get more head-and-neck cancer patients to radiation therapy on time.